Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition. - Wikidata - wikimedia - TriplyDB

Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.

Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.

http://www.wikidata.org/entity/Q34486201

about

PI3K mutations in breast cancer: prognostic and therapeutic implications Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer.In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins.Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.

P2860

Q28081992-30CBD5EF-1223-4DAC-8590-EB8493FD5822 Q36355880-D7EC51A1-FFBD-49C5-8392-B2FBBFA22C6D Q37206520-241C1C16-DAD4-45EB-97FD-79279477A993 Q37570653-EFA6B262-23A7-47EF-9679-F8BF203554DB Q37694812-9C5797A1-B46D-447A-B5CD-7AF3B403EB50 Q37695410-A724B50F-995A-456F-BE1B-BDCEC1386AE8 Q38752466-5DF5BE68-A0FE-4919-A04A-8865B8A5B878 Q39920942-4AFF3EDD-D314-4008-9A78-95D08322FC4D Q55003988-D5AC8CDE-A7EC-4DCC-BDEA-EFE605CF7623

P2860

Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.

http://www.wikidata.org/entity/Q34486201

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Relationship of PIK3CA mutatio ...... ponse to aromatase inhibition.

@ast

Relationship of PIK3CA mutatio ...... ponse to aromatase inhibition.

@en

Relationship of PIK3CA mutatio ...... ponse to aromatase inhibition.

@nl

type

label

Relationship of PIK3CA mutatio ...... ponse to aromatase inhibition.

@ast

Relationship of PIK3CA mutatio ...... ponse to aromatase inhibition.

@en

Relationship of PIK3CA mutatio ...... ponse to aromatase inhibition.

@nl

prefLabel

Relationship of PIK3CA mutatio ...... ponse to aromatase inhibition.

@ast

Relationship of PIK3CA mutatio ...... ponse to aromatase inhibition.

@en

Relationship of PIK3CA mutatio ...... ponse to aromatase inhibition.

@nl

P1433

Q34486201-8014ADA7-E7FF-4287-8590-43A913BE95C1

P1476

Q34486201-D132854B-32E6-4576-9FEF-BB7EFE2E66CA

P2093

Q34486201-0D91B1EA-F1A8-475F-B607-68B29185C959

Q34486201-14800677-2060-4BC8-8E1A-A5493A8E52DE

Q34486201-5C04D61E-3567-4778-B910-D433797A2894

Q34486201-83D90EE3-293C-404D-B017-91F5D8104DA7

Q34486201-8E6F3B54-5623-445B-B148-39BFB17F87F1

Q34486201-BA833B58-F99E-4ABA-8A7B-12F754838002

Q34486201-EACF884D-382E-4D2C-ABDE-A40B34219C6A

P2860

Q34486201-15940832-9334-40BE-AA9D-38AED0966F5A

Q34486201-2319A38F-DF2E-4296-B42A-366E256978DF

Q34486201-2BADCF93-687E-4EA2-B664-74D09DFEEC1E

Q34486201-2D738317-883A-40A5-9978-A4224D868FA8

Q34486201-2F0124D8-AB9A-461E-B887-B1459D25111E

Q34486201-3D043F7A-6E16-451C-BD99-BFEB831F3121

Q34486201-3F298D1A-CEDD-47F6-9DF3-0CDEB096E619

Q34486201-42567D01-DE09-48C4-994A-547AB48D2985

Q34486201-68E957B6-14F8-4D70-BDE1-13C9F08358AB

Q34486201-69B99836-4988-41CB-AEB4-390C3691DB25

P2888

Q34486201-0EE137D2-265B-49D7-9B91-650DA30D5BBE

P304

Q34486201-1E0E2CB4-CC7D-4DF4-95BE-9B0B2B7489CF

P31

Q34486201-846D9420-AD79-440E-B936-825DCFBB8530

P356

Q34486201-6032550A-C9E2-493D-A543-529BDCECE356

P433

Q34486201-79EA9C9F-963E-4361-81A1-155234735FD6

P478

Q34486201-8C80E48A-C3A1-49F2-99DB-3437332E6AEC

P50

Q34486201-441A9E79-3FCD-424B-98A1-5E014117667C

P577

Q34486201-E403D278-B324-4583-B973-AD0B19982CEC

P5875

Q34486201-1C5A5A36-53B6-45B7-A3F6-4AF751855D30

P6179

Q34486201-A09BE413-D860-493D-A550-4566568303F4

P698

Q34486201-520A39D4-AFD2-4A9F-B5FF-0ED1370AD831

P932

Q34486201-2CB82F18-785D-4EB0-9A85-4F4CFDFD3829

P356

P1433

Breast Cancer Research

P1476

Relationship of PIK3CA mutatio ...... ponse to aromatase inhibition.

@en

P2093

Corrinne V Segal

http://www.w3.org/2001/XMLSchema#string

Elena López-Knowles

http://www.w3.org/2001/XMLSchema#string

Ian Smith

http://www.w3.org/2001/XMLSchema#string

Isaac Garcia-Murillas

http://www.w3.org/2001/XMLSchema#string

Lesley-Ann Martin

http://www.w3.org/2001/XMLSchema#string

Nicholas C Turner

http://www.w3.org/2001/XMLSchema#string

Qiong Gao

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive molecular portraits of human breast tumours

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Whole-genome analysis informs breast cancer response to aromatase inhibition

An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors

Identification of genes periodically expressed in the human cell cycle and their expression in tumors

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

The molecular portraits of breast tumors are conserved across microarray platforms.

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.

P2888

P304

R68

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR3683

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263585128

http://www.w3.org/2001/XMLSchema#string

P6179

1047396808

http://www.w3.org/2001/XMLSchema#string

P698

24981670

http://www.w3.org/2001/XMLSchema#string

P932

4227109

http://www.w3.org/2001/XMLSchema#string